RegeneCure will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics.

Under the terms of the agreement, RegeneCure has received the worldwide exclusive right to develop and commercialize the technology. In return, Yissum and Hadasit will receive license fees, milestones and royalty payments from future sales of the final product.

The membrane implant has a microporous surface that facilitates adherence of bone stem cells (MSCs) recruited to the injured site through chemotaxis.

The membrane optimizes proliferation and differentiation of the MSCs into bone tissue in the area of need and also serves as an effective barrier that does not allow scar tissue to infiltrate into the fracture and slow down the regenerative healing process.

The membrane implant is recognized as a medical device, enabling an expedited regulatory pathway.